Editas Medicine Analyst Price Targets

Editas Medicine Inc

EDITNASDAQ

$2.56

-0.02-0.78%

Dern. MÀJ: Sep 28, 9:20 AM

Wall Street analyst price targets and consensus rating for Editas Medicine (EDIT).

Price Target Range — 11 Quarters

Analyst Consensus — 14 Analysts

10Buy

3Hold

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$7Upside to Avg. PT+159.8%

Rating Trend — Last 9 Months

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Guggenheim	Debjit Chattopadhyay	Upgrade	Neutral→Buy	$5
Aug 18, 2026	Ladenburg Thalmann	—	Initiate	Buy	$6
May 5, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$4→$4
Mar 10, 2026	Jones Trading	Soumit Roy	Upgrade	Hold→Buy	$8
Mar 9, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$4
Sep 5, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$5
Sep 3, 2025	Wells Fargo	Yanan Zhu	PT Raise	Equal-Weight	$3→$4
Aug 15, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$3→$5
Aug 13, 2025	Baird	Joel Beatty	PT Raise	Outperform	$4→$6
May 13, 2025	Baird	Joel Beatty	PT Cut	Outperform	$8→$4
Apr 28, 2025	HC Wainwright & Co.	Mitchell Kapoor	Initiate	Buy	$3
Dec 16, 2024	Evercore ISI Group	Liisa Bayko	PT Cut	Outperform	$7→$5
Dec 16, 2024	JP Morgan	Brian Cheng	Downgrade	Neutral→Underweight	—
Dec 13, 2024	RBC Capital	Luca Issi	PT Cut	Sector Perform	$5→$4
Dec 13, 2024	Barclays	Gena Wang	PT Cut	Equal-Weight	$5→$3
Dec 13, 2024	Chardan Capital	Geulah Livshits	Downgrade	Buy→Neutral	—
Dec 13, 2024	Baird	Joel Beatty	PT Cut	Outperform	$10→$8
Dec 13, 2024	Stifel	Dae Gon Ha	Downgrade	Buy→Hold	$11→$3
Dec 11, 2024	Wells Fargo	Yanan Zhu	Downgrade	Overweight→Equal-Weight	$7→$4
Nov 5, 2024	Chardan Capital	Geulah Livshits	Maintained	Buy	$12